See every side of every news story
Get Started
SubscribeLogin
Published • loading... • Updated

Efficacy Results From the Barzolvolimab Trial

Summary by dermatologytimes.com
An expert discusses how barzolvolimab demonstrated statistically significant and clinically meaningful reductions in UAS7 scores, with over 50% of patients achieving complete response and sustained disease control lasting 28 weeks after the final dose.
DisclaimerThis story is only covered by news sources that have yet to be evaluated by the independent media monitoring agencies we use to assess the quality and reliability of news outlets on our platform. Learn more here.

1 Articles

dermatologytimes.comdermatologytimes.com

Efficacy Results From the Barzolvolimab Trial

An expert discusses how barzolvolimab demonstrated statistically significant and clinically meaningful reductions in UAS7 scores, with over 50% of patients achieving complete response and sustained disease control lasting 28 weeks after the final dose.

Read Full Article
Think freely.Subscribe and get full access to Ground NewsSubscriptions start at $9.99/yearSubscribe

Bias Distribution

  • There is no tracked Bias information for the sources covering this story.

Factuality 

To view factuality data please Upgrade to Premium

Ownership

To view ownership data please Upgrade to Vantage

dermatologytimes.com broke the news in on Friday, August 1, 2025.
Sources are mostly out of (0)
Stories disproportionately reported by the Left or the Right

Similar News Topics

News
For You
SearchBlindspotLocal